The researchers found that xenograft tumours from “double-hit” cell lines had increased MMP-2 and MMP-9 activity compared to tumours from “single-hit” cell lines, which could also account, in part, for the poor clinical outcome of HNSCC patients with the “double-hit” profile [58]. This evidence concerns the gene MMP9 and neoplasm.